Viralytics raises $4.7m to fund melanoma trial

By Staff Writers
Tuesday, 20 December, 2011

Viralytics has announced it has raised $4.7 million in a share purchase plan, which has raised the company’s cash reserves to over $8 million.

The fund raising was undertaken to coincide with the commencement of patient enrolment in the company’s US-based phase II melanoma trial.

The issue price of the shares was 30.84c and was based on the five day volume weighted price as of 14 December.

Viraltyics’ (ASX:VLA) share price dropped 5.5% to 34c by mid-afternoon, down from 36c at Monday’s close.

Related News

Anti-inflammatory agent could decrease septic shock mortality

Researchers have discovered a naturally occurring blood protein — a type of...

Less penicillin needed to treat Strep A infection than we thought

It's never been known exactly how much penicillin prevents sore throats — the most...

Stress disrupts emotion control in mental illness

Acute stress may impair key brain functions involved in managing emotions — particularly in...


  • All content Copyright © 2025 Westwick-Farrow Pty Ltd